NMC
PRLD icon

Nine Masts Capital’s Prelude Therapeutics PRLD Stock Holding History

Nine Masts Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,699
Closed -$40K – 268
2026
Q1 		$40K Buy
+11,699
New +$30.7K 0.01% 180

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Nine Masts Capital's PRLD Position: Q2 2026 in Review

Nine Masts Capital sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 11,699 shares — an estimated $40K sold.

Nine Masts Capital first reported a position in PRLD in Q1 2026 and held it in 1 quarter. The position peaked at $40K in Q1 2026. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Nine Masts Capital reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 11,699 Prelude Therapeutics shares in Q2 2026, an estimated $40K.
  • Nine Masts Capital first reported a position in Prelude Therapeutics in Q1 2026 and held it in 1 quarter.
  • Nine Masts Capital's Prelude Therapeutics position peaked at $40K in Q1 2026.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.